Ensysce Biosciences, Inc. - ENSC
About Gravity Analytica
Recent News
- 05.15.2026 - Ensysce Biosciences Reports First Quarter 2026 Financial Results
- 05.12.2026 - Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
- 05.08.2026 - Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
- 04.16.2026 - Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
- 04.07.2026 - Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
- 03.30.2026 - Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Recent Filings
- 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
- 05.15.2026 - EX-99.1 EX-99.1
- 05.15.2026 - 8-K Current report
- 04.30.2026 - S-8 Securities to be offered to employees in employee benefit plans
- 04.15.2026 - EFFECT Notice of Effectiveness
- 04.14.2026 - CORRESP Correspondence
- 04.13.2026 - UPLOAD SEC-generated letter
- 04.09.2026 - S-3 Registration statement under Securities Act of 1933
- 04.08.2026 - 8-K Current report
- 04.08.2026 - EX-99.1 EX-99.1